Post treatment CIN, cytology and hrHPV testing.
Conditions
Interventions
During follow-up after treatment for high-grade CIN (6, 12 and 24 months) cytology and hrHPV testing will be performed. Colposcopic examinations will be performed in case of abnormal cervical cytology
Sponsors
Department of Obstetrics and Gynaecology, Erasmus University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands. phone:+31-10-4633381
Email: t.helmerhorst@erasmusmc.nl
Fax: +31-10-4633315
Eligibility
Inclusion criteria
Inclusion criteria: Women indicated to be treated for high-grade CIN lesions.
Exclusion criteria
Exclusion criteria: 1. Previous treatment for high-grade CIN; 2. An immune compromised state; 3. Previous or current cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome parameter is the reduction in the number of false-positives achieved by combined testing, through increasing the specificity of testing with unaltered sensitivity, resulting in fewer diagnostic procedures. | — |
Secondary
| Measure | Time frame |
|---|---|
| This will secondarily lead to a decrease in unnecessary examinations and treatment. Possible influence of hrHPV genotyping and effects on health-costs were assessed. | — |
Contacts
Public ContactThJM Helmerhorst
Department of Obstetrics and Gynaecology, Erasmus University Medical Center Rotterdam, P.O. Box 2040
Outcome results
None listed